Search

Your search keyword '"Zanabili, Joud"' showing total 13 results
Start Over Author "Zanabili, Joud"
13 results on '"Zanabili, Joud"'

1. Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy

Author

Bailén, Rebeca, primary, Alenda, Raquel, additional, Herruzo-Delgado, Beatriz, additional, Acosta-Fleitas, Cynthia, additional, Vallés, Ana, additional, Esquirol, Albert, additional, Fonseca, Marta, additional, Solán, Laura, additional, Sánchez-Vadillo, Irene, additional, Bautista, Guiomar, additional, Bento, Leyre, additional, López-Godino, Oriana, additional, Pérez-Martínez, Ariadna, additional, Torrent, Anna, additional, Zanabili, Joud, additional, Calbacho, María, additional, Moreno, Miguel Ángel, additional, Pascual-Cascón, María Jesús, additional, Guerra-Domínguez, Luisa, additional, Chinea, Anabelle, additional, García-Cadenas, Irene, additional, López-Corral, Lucía, additional, Boix-Giner, Francisco, additional, López Lorenzo, José Luis, additional, Humala, Karem, additional, Duarte, Rafael, additional, Sampol, Antonia, additional, Heras, Inmaculada, additional, Vicario, José Luis, additional, Balas, Antonio, additional, Oarbeascoa, Gillen, additional, Fernández-Caldas, Paula, additional, Anguita, Javier, additional, and Kwon, Mi, additional

Published
2023
Full Text
View/download PDF

2. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers

Author

Novelli, Silvana, Bento, Leyre, Garcia, Irene, Prieto, Laura, López, Lucía, Gutierrez, Gonzalo, Hernani, Rafael, Pérez, Ariadna, Esquirol, Albert, Solano, Carlos, Bastos, Mariana, Dorado, Nieves, Rodríguez, Nancy, Rodríguez, Guillermo, Piñana, Jose L., Montoro, Juan, Herrera, Pilar, Luna, Alejandro, Parody, Rocío, Martín, Carmen, García, Estefanía, López, Oriana, Heras, Inmaculada, Zanabili, Joud, Moraleda, Jose M., Yañez, Lucrecia, Gutierrez, Antonio, Zudaire, Teresa, Córdoba, Raúl, Varela, Rosario, Ferra, Christelle, Martínez, Joaquin, Martínez, Carmen, Gonzalez-Barca, Eva, Martino, Rodrigo, and Caballero, Dolores

Published
2021
Full Text
View/download PDF

3. Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups

Author

Rey-Búa, Beatriz, primary, Cabrero, Mónica, additional, Bento, Leyre, additional, Montoro, Juan, additional, Bastos-Oreiro, Mariana, additional, Parody, Rocío, additional, Yañez, Lucrecia, additional, Lopez-Godino, Oriana, additional, Zanabili, Joud, additional, Herrera, Pilar, additional, Gutierrez, Gonzalo, additional, Perez, Ariadna, additional, Piñana, Jose L., additional, Novelli, Silvana, additional, Cortés, María, additional, Sureda, Ana Maria, additional, Caballero, Dolores, additional, and García-Sancho, Alejandro Martín, additional

Published
2022
Full Text
View/download PDF

4. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience

Author

Gutierrez, Antonio, Bento, Leyre, Novelli, Silvana, Martin, Alejandro, Gutierrez, Gonzalo, Queralt Salas, Maria, Bastos-Oreiro, Mariana, Perez, Ariadna, Hernani, Rafael, Cruz Viguria, Maria, Lopez-Godino, Oriana, Montoro, Juan, Pinana, Jose Luis, Ferra, Christelle, Parody, Rocio, Martin, Carmen, Espanol, Ignacio, Yanez, Lucrecia, Rodriguez, Guillermo, Zanabili, Joud, Herrera, Pilar, Varela, Maria Rosario, Sampol, Antonia, Solano, Carlos, Caballero, Dolores, On Behalf Of The Grupo Espanol de Trasplante de Progenitores, Hematopoyeticos Geth And Grupo Espanol de Linfoma Y Trasplante Autologo, and Geltamo

Subjects
CAR-T cell therapy, graft-versus-lymphoma effect, non-relapse mortality, target therapy, acute graft-versus-host disease, allogeneic stem-cell transplantation, mantle cell lymphoma
Abstract

Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3-4 aGVHD were associated with a higher NRM. Grade 3-4 aGVHD, donor type (mismatch non-related), and the time-period 2006-2020 were independently related to worse EFS. Patients from 1995-2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.

Published
2022

5. Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience from the Spanish Group of Hematopoietic Transplant (GETH-TC)

Author

Bailen, Rebeca, primary, Vicario, Jose Luis, additional, Herruzo, Beatriz, additional, Guerra, Luisa Maria, additional, Vallés, Ana, additional, Esquirol, Albert, additional, Fonseca, Marta, additional, Solán, Laura, additional, Sanchez Vadillo, Irene, additional, Bento, Leyre, additional, Pérez Martínez, Ariadna, additional, Torrent, Anna, additional, Zanabili, Joud, additional, Calbacho, Maria, additional, Alenda, Raquel, additional, Moreno, Miguel Ángel, additional, Gago, Beatriz, additional, Chinea, Anabelle, additional, García-Cadenas, Irene, additional, Boix-Giner, Francisco, additional, López Lorenzo, José Luis, additional, Humala, Karem, additional, Acosta-Fleitas, Cynthia, additional, Sampol, Antonia, additional, Oarbeascoa, Gillen, additional, Anguita, Javier, additional, Diez-Martin, Jose L., additional, and Kwon, Mi, additional

Published
2021
Full Text
View/download PDF

6. Autologous Stem Cell Transplantation Remains a Curative Option As Second Line Treatment for Patients with Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geth-TC/Geltamo Study

Author

Bento, Leyre, Gutiérrez, Antonio, Martínez, Carmen, Ortí, Consejo, Sorribes, Marina, Caballero, Ana Carolina, Peña, Marta, Pérez, Ariadna, Jimenez Ubieto, Ana, Bastos-Oreiro, Mariana, Fernández Caldas-González, Paula, Navarro, Belén, Salcedo, Isabel, Abrisqueta Costa, Pau, Español, Ignacio, Cornago, Javier, Martín-Moro, Fernando, García, Lucía, Gómez, Pilar, Varela, Rosario, Puente, María, Zanabili, Joud, Zudaire, Teresa, Zeberio, Izaskun, Del Campo, Raquel, González, Leslie, Gonzalez-Sierra, Pedro, Blázquez Goñi, Cristina, Rovira, Jordina, Sitges, Marta, Franch, Mireia, Cabero, Almudena, Mussetti, Alberto, Montoro, Juan, Sampol Mayol, Antonia, Sureda Balari, Anna Maria, Caballero, Dolores, and Martín García-Sancho, Alejandro

Published
2023
Full Text
View/download PDF

7. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

Author

Bento, Leyre, Gutiérrez, Antonio, Novelli, Silvana, Montoro, Juan, Piñana, José Luis, López-Corral, L., Cabrero, Mónica, Martín-Sancho, Alejandro, Gutiérrez-García, Gonzalo, Ortíz-Moscovich, Marcela, Bastos-Oreiro, Mariana, Dorado, Nieves, Pérez, Ariadna, Hernani, Rafael, Ferrá, Christelle, Parody, Rocío, García-Cadenas, Irene, Herrera, Pilar, Rodríguez-Real, Guillermo, Rodríguez, Nancy, Martín, Carmen, Yáñez, Lucrecia, Zanabili, Joud, Varela, María Rosario, López-Godino, Oriana, Heras, Inmaculada, Español, Ignacio, Martínez, Carmen, Pérez-Simón, José A., Solano, Carlos, Sureda, Anna, Sierra, Jordi, Sampol, Antonia, Caballero, Dolores, Bento, Leyre, Gutiérrez, Antonio, Novelli, Silvana, Montoro, Juan, Piñana, José Luis, López-Corral, L., Cabrero, Mónica, Martín-Sancho, Alejandro, Gutiérrez-García, Gonzalo, Ortíz-Moscovich, Marcela, Bastos-Oreiro, Mariana, Dorado, Nieves, Pérez, Ariadna, Hernani, Rafael, Ferrá, Christelle, Parody, Rocío, García-Cadenas, Irene, Herrera, Pilar, Rodríguez-Real, Guillermo, Rodríguez, Nancy, Martín, Carmen, Yáñez, Lucrecia, Zanabili, Joud, Varela, María Rosario, López-Godino, Oriana, Heras, Inmaculada, Español, Ignacio, Martínez, Carmen, Pérez-Simón, José A., Solano, Carlos, Sureda, Anna, Sierra, Jordi, Sampol, Antonia, and Caballero, Dolores

Abstract

We performed a retrospective multicenter study including 140 patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who underwent allogeneic hematopoietic stem cell transplantation (allo-SCT) from March 1995 to November 2018. Our objective was to analyze long term outcomes. Seventy-four percent had received a previous auto-SCT (ASCT) and the median number of lines pre-allo-SCT was 3 (range 1–9). Three year-event free survival (EFS) and overall survival (OS) were 38% and 44%, respectively. Non-relapse mortality (NRM) at day 100 was 19%. Cumulative incidence of grade III–IV acute graft versus host disease (GVHD) at day 100 was 16% and moderate/severe chronic GVHD at 3 years 34%. Active disease at allo-SCT (HR 1.95, p = 0.039) (HR 2.19, p = 0.019), HCT-CI ≥ 2 (2.45, p = 0.002) (HR 2.33, p = 0.006) and donor age >37 years (HR 2.75, p = 0.014) (HR 1.98, p = 0.043) were the only independent variables both for PFS and OS, respectively. NRM was significantly modified by HCT-CI ≥ 2 (HR 4.8, p = 0.008), previous ASCT (HR 4.4, p = 0.048) and grade III–IV acute GVHD on day 100 (HR 6.13, p = 0.016). Our data confirmed that allo-SCT is a curative option for patients with R/R DLBCL, displaying adequate results for fit patients with chemosensitive disease receiving an allo-SCT from a young donor.

Published
2021

8. Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive Progression

Author

Gonzalez-Rodriguez, Ana P., primary, Payer, Angel R., additional, Menendez-Suarez, Juan J., additional, Sordo-Bahamonde, Christian, additional, Lorenzo-Herrero, Seila, additional, Zanabili, Joud, additional, Fonseca, Ariana, additional, Gonzalez-Huerta, Ana Julia, additional, Palomo, Pilar, additional, and Gonzalez, Segundo, additional

Published
2020
Full Text
View/download PDF

9. Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime

Author

Novelli, Silvana, primary, Bento, Leyre, additional, García-Cadenas, Irene, additional, Prieto, Laura, additional, Corral, Lucía López, additional, Gutierrez Garcia, Gonzalo, additional, Hernani, Rafael, additional, Pérez Martínez, Ariadna, additional, Sierra, Jorge, additional, Solano, Carlos, additional, Bastos-Oreiro, Mariana, additional, Dorado, Nieves, additional, Rodríguez-Torres, Nancy, additional, Rodríguez, Guillermo, additional, Piñana Sanchez, Jose Luis, additional, Montoro Gómez, Juan, additional, Herrera Puente, Pilar, additional, Luna, Alejandro, additional, Sanchez Ortega, Isabel, additional, Martin Calvo, Carmen, additional, López-Godino, Oriana, additional, Heras, Inmaculada, additional, Zanabili, Joud, additional, Palomo Moraleda, María Del Pilar, additional, Parody, Rocio, additional, Moraleda, Jose Maria, additional, Yáñez, Lucrecia, additional, Gutiérrez, Antonio, additional, Zudaire, Teresa, additional, Cordoba, Raul, additional, Varela, Rosario, additional, Ferra, Christelle M, additional, Martinez-Lopez, Joaquin, additional, García-Torres, Estefania, additional, and Caballero, Dolores, additional

Published
2019
Full Text
View/download PDF

10. Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors

Author

Montoro, Juan, Chorão, Pedro, Bento, Leyre, Cabrero, Mónica, Martín, Carmen, Novelli, Silvana, Cadenas, Irene García, Gutiérrez, Gonzalo, López-Godino, Oriana, Ferrá, Christelle, Bastos-Oreiro, Mariana, Pérez, Ariadna, Parody, Rocío, Pérez Simón, José A., Yañez, Lucrecia, Sánchez, Andrés, Zanabili, Joud, Varela, Ma Rosario, Córdoba, Raúl, Zudaire, Teresa, Jiménez-Ubieto, Ana, Sanz, Jaime, Sureda, Ana, Caballero, Dolores, and Piñana, José Luis

Published
2021
Full Text
View/download PDF

11. Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (FL): Results from A Retrospective Multicenter Study From Gelth/geltamo Group

Author

Rey Bua, Beatriz, Cabrero, Monica, Bento, Leyre, Lopez-Parra, Miriam, Montoro, Juan, Dorado, Nieves, Bastos, Mariana, Gutierrez-Garcia, Gonzalo, Lopez Godino, Oriana, Yanez, Lucrecia, Lopez Corral, Lucia, Prieto, Laura, Fonseca, Marta, Novelli, Silvana, Ferra, Christelle, Herrera, Pilar, Carlos Grande García, Zanabili, Joud, Sanchez-Ortega, Isabel, Parody, Rocio, Martin, Alejandro, and Dolores Caballero, M.

12. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.

Author

Gutierrez A, Bento L, Novelli S, Martin A, Gutierrez G, Queralt Salas M, Bastos-Oreiro M, Perez A, Hernani R, Cruz Viguria M, Lopez-Godino O, Montoro J, Piñana JL, Ferra C, Parody R, Martin C, Español I, Yañez L, Rodriguez G, Zanabili J, Herrera P, Varela MR, Sampol A, Solano C, Caballero D, and On Behalf Of The Grupo Español de Trasplante de Progenitores Hematopoyéticos Geth And Grupo Español de Linfoma Y Trasplante Autólogo Geltamo

Abstract

Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3-4 aGVHD were associated with a higher NRM. Grade 3-4 aGVHD, donor type (mismatch non-related), and the time-period 2006-2020 were independently related to worse EFS. Patients from 1995-2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.

Published
2022
Full Text
View/download PDF

13. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study.

Author

Bento L, Gutiérrez A, Novelli S, Montoro J, Piñana JL, López-Corral L, Cabrero M, Martín-Sancho A, Gutiérrez-García G, Ortiz-Moscovich M, Bastos-Oreiro M, Dorado N, Pérez A, Hernani R, Ferrà C, Parody R, García-Cadenas I, Herrera P, Rodríguez G, Rodríguez N, Martín C, Yáñez L, Zanabili J, Varela MR, López-Godino O, Heras I, Español I, Martínez C, Pérez-Simón JA, Solano C, Sureda A, Sierra J, Sampol A, and Caballero D

Subjects
Adult, Humans, Neoplasm Recurrence, Local, Retrospective Studies, Transplantation Conditioning, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Lymphoma, Large B-Cell, Diffuse therapy
Abstract

We performed a retrospective multicenter study including 140 patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who underwent allogeneic hematopoietic stem cell transplantation (allo-SCT) from March 1995 to November 2018. Our objective was to analyze long term outcomes. Seventy-four percent had received a previous auto-SCT (ASCT) and the median number of lines pre-allo-SCT was 3 (range 1-9). Three year-event free survival (EFS) and overall survival (OS) were 38% and 44%, respectively. Non-relapse mortality (NRM) at day 100 was 19%. Cumulative incidence of grade III-IV acute graft versus host disease (GVHD) at day 100 was 16% and moderate/severe chronic GVHD at 3 years 34%. Active disease at allo-SCT (HR 1.95, p = 0.039) (HR 2.19, p = 0.019), HCT-CI ≥ 2 (2.45, p = 0.002) (HR 2.33, p = 0.006) and donor age >37 years (HR 2.75, p = 0.014) (HR 1.98, p = 0.043) were the only independent variables both for PFS and OS, respectively. NRM was significantly modified by HCT-CI ≥ 2 (HR 4.8, p = 0.008), previous ASCT (HR 4.4, p = 0.048) and grade III-IV acute GVHD on day 100 (HR 6.13, p = 0.016). Our data confirmed that allo-SCT is a curative option for patients with R/R DLBCL, displaying adequate results for fit patients with chemosensitive disease receiving an allo-SCT from a young donor., (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results